Prescriptions for weight loss drugs semaglutide and tirzepatide have continued their rapid growth trend through 2025. The surge reflects growing demand for GLP-1 medications that are reshaping how patients and doctors approach obesity treatment. BusinessWorld Online reports on the sustained climb in prescriptions and what it signals for the market. The trend underscores how quickly these drugs have moved from niche treatments to mainstream health staples.
Source: headlinesplus.com